Innovative technology for cancer risk analysis

S. Tommas, K. Danza, B. Pilato, S. de Summa

Research output: Contribution to journalArticle

Abstract

After completion of the Human Genome Project, analysis of genetic and genomic variations in different pathological states became possible. The capillary system based on Sanger methods is still very expensive in terms of time, cost and professionalism required. For this reason, the National Human Genome Institute proposed an 'advanced sequencing technology development' project with the aim of sequencing a genome in 1 day for $1000. Three validated platforms are commercially available and single molecule sequencing methods have been recently introduced, which are not only competitive in time and costs, but display greater accuracy than 'past generation' sequencing. Next generation technology allows, in a single experiment, the identification of copy number variation and large rearrangements, or detection of fusion transcripts analysis thus permitting the evaluation of cancer risk at multiple levels (genomic, transcriptomic, proteomic, epigenetic).

Original languageEnglish
JournalAnnals of Oncology
Volume22
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • Cancer
  • Genome
  • Methylome
  • Next generation
  • Proteome
  • Transcriptome

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Innovative technology for cancer risk analysis'. Together they form a unique fingerprint.

  • Cite this

    Tommas, S., Danza, K., Pilato, B., & de Summa, S. (2011). Innovative technology for cancer risk analysis. Annals of Oncology, 22(SUPPL. 1). https://doi.org/10.1093/annonc/mdq664